Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine the efficacy of SAR441344 as measured by reduction of the number of new active
brain lesions
Secondary Objective:
- To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures
- To evaluate the safety and tolerability of SAR441344
- To evaluate pharmacokinetics of SAR441344